Skip to content
2000
Volume 23, Issue 3
  • ISSN: 1871-5257
  • E-ISSN: 1875-6182

Abstract

Introduction

This report discusses a rare case involving a patient with high-risk (HR) Del(5q) myelodysplastic syndrome (MDS) who achieved a long-term response to lenalidomide after having received six cycles of azacytidine. The latter treatment led to the clearance of blast cells from the bone marrow (BM).

Case Representation

As per current clinical practice, patients with HR MDS receive azacytidine continuously until the disease progresses or the occurrence of unmanageable side effects. However, in this case, the patient decided to interrupt hypomethylation therapy. Due to the patient's preference for oral therapy at home, the absence of blast cells, the ongoing need for transfusions, and a cytogenetic abnormality-predictive response to lenalidomide, the choice of the latter agent allowed for a sustained response lasting up to 68 months.

Conclusion

Our observations suggest that further studies could explore the sequential use of azacytidine followed by lenalidomide after achieving BM blast clearance in patients with HR MDS with del(5q).

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chamc/10.2174/0118715257341062250130103015
2025-02-11
2026-02-05

  • From This Site

    /content/journals/chamc/10.2174/0118715257341062250130103015
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ArberD.A. OraziA. HasserjianR.P. BorowitzM.J. CalvoK.R. KvasnickaH.M. WangS.A. BaggA. BarbuiT. BranfordS. Bueso-RamosC.E. CortesJ.E. Dal CinP. DiNardoC.D. DombretH. DuncavageE.J. EbertB.L. EsteyE.H. FacchettiF. FoucarK. GangatN. GianelliU. GodleyL.A. GökbugetN. GotlibJ. Hellström-LindbergE. HobbsG.S. HoffmanR. JabbourE.J. KiladjianJ.J. LarsonR.A. Le BeauM.M. LohM.L.C. LöwenbergB. MacintyreE. MalcovatiL. MullighanC.G. NiemeyerC. OdenikeO.M. OgawaS. OrfaoA. PapaemmanuilE. PassamontiF. PorkkaK. PuiC.H. RadichJ.P. ReiterA. RozmanM. RudeliusM. SavonaM.R. SchifferC.A. Schmitt-GraeffA. ShimamuraA. SierraJ. StockW.A. StoneR.M. TallmanM.S. ThieleJ. TienH.F. TzankovA. VannucchiA.M. VyasP. WeiA.H. WeinbergO.K. WierzbowskaA. CazzolaM. DöhnerH. TefferiA. International consensus classification of myeloid neoplasms and acute leukemias: Integrating morphologic, clinical, and genomic data.Blood2022140111200122810.1182/blood.202201585035767897
     [Google Scholar]
  2. Hellström-LindbergE.S. KrögerN. Clinical decision-making and treatment of myelodysplastic syndromes.Blood2023142262268228110.1182/blood.202302007937874917
     [Google Scholar]
  3. NiscolaP. GianfeliciV. GiovanniniM. PiccioniD. MazzoneC. de FabritiisP. Latest insights and therapeutic advances in myelodysplastic neoplasms.Cancers2024168156310.3390/cancers1608156338672645
     [Google Scholar]
  4. DöhnerH. WieA.H. AppelbaumF.R. Diagnosis and management of acute myeloid leukemia in adults: 2022 recommendations from an International Expert Panel, on behalf of the European LeukemiaNet.Blood2022140121345137710.1182/blood.202201686735797463
     [Google Scholar]
  5. NiscolaP. GianfeliciV. CatalanoG. GiovanniniM. MazzoneC. NogueraN.I. de FabritiisP. Acute myeloid leukemia in older patients: From new biological insights to targeted therapies.Curr. Oncol.202431116632665810.3390/curroncol3111049039590121
     [Google Scholar]
  6. KhouryJ.D. SolaryE. AblaO. The 5th edition of the world health organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms.Leukemia202236717031719
     [Google Scholar]
  7. BersanelliM. TravaglinoE. MeggendorferM. MatteuzziT. SalaC. MoscaE. ChiereghinC. Di NanniN. GnocchiM. ZampiniM. RossiM. MaggioniG. TermaniniA. AngelucciE. BernardiM. BorinL. BrunoB. BonifaziF. SantiniV. BacigalupoA. VosoM.T. OlivaE. RivaM. UbezioM. MorabitoL. CampagnaA. SaittaC. SavevskiV. GiampieriE. RemondiniD. PassamontiF. CiceriF. BolliN. RambaldiA. KernW. KordastiS. SoleF. PalomoL. SanzG. SantoroA. PlatzbeckerU. FenauxP. MilanesiL. HaferlachT. CastellaniG. Della PortaM.G. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes.J. Clin. Oncol.202139111223123310.1200/JCO.20.0165933539200
     [Google Scholar]
  8. NingY. ZhangY. KallenM.A. EmadiA. BaerM.R. Cytogenetics and molecular genetics of myelodysplastic neoplasms.Best Pract. Res. Clin. Haematol.202336410151210.1016/j.beha.2023.10151238092472
     [Google Scholar]
  9. AchaP. MalloM. SoléF. Myelodysplastic syndromes with isolated del(5q): Value of molecular alterations for diagnostic and prognostic assessment.Cancers20221422553110.3390/cancers1422553136428627
     [Google Scholar]
  10. VenugopalS. MascarenhasJ. SteensmaD.P. Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences.Blood Rev.20214610073510.1016/j.blre.2020.10073532736878
     [Google Scholar]
  11. BruzzeseA. MartinoE.A. MendicinoF. LuciaE. OlivitoV. CapodannoI. NeriA. MorabitoF. VignaE. GentileM. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.Eur. J. Haematol.2024112686086910.1111/ejh.1418138294126
     [Google Scholar]
  12. BernardE. HasserjianR.P. GreenbergP.L. Arango OssaJ.E. CreignouM. TuechlerH. Gutierrez-AbrilJ. DomenicoD. Medina-MartinezJ.S. LevineM. LiosisK. FarnoudN. SirenkoM. JäderstenM. GermingU. SanzG. van de LoosdrechtA.A. NannyaY. KosmiderO. FolloM.Y. TholF. ZamoraL. PinheiroR.F. PellagattiA. EliasH.K. HaaseD. GansterC. AdesL. TobiassonM. PalomoL. Della PortaM.G. FenauxP. BelickovaM. SavonaM.R. KlimekV.M. SantosF.P.S. BoultwoodJ. KotsianidisI. SantiniV. SoléF. PlatzbeckerU. HeuserM. ValentP. FinelliC. VosoM.T. ShihL.Y. FontenayM. JansenJ.H. CerveraJ. GattermannN. EbertB.L. BejarR. MalcovatiL. OgawaS. CazzolaM. Hellström-LindbergE. PapaemmanuilE. Molecular taxonomy of myelodysplastic syndromes and its clinical implications.Blood2024144151617163210.1182/blood.202302372738958467
     [Google Scholar]
  13. KrönkeJ. FinkE.C. HollenbachP.W. MacBethK.J. HurstS.N. UdeshiN.D. ChamberlainP.P. ManiD.R. ManH.W. GandhiA.K. SvinkinaT. SchneiderR.K. McConkeyM. JäråsM. GriffithsE. WetzlerM. BullingerL. CathersB.E. CarrS.A. ChopraR. EbertB.L. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.Nature2015523755918318810.1038/nature1461026131937
     [Google Scholar]
  14. PetzoldG. FischerE.S. ThomäN.H. Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase.Nature2016532759712713010.1038/nature1697926909574
     [Google Scholar]
  15. FuchsO. Treatment of lymphoid and myeloid malignancies by immunomodulatory drugs.Cardiovasc. Hematol. Disord. Drug Targets2019191517810.2174/1871529X1866618052207385529788898
     [Google Scholar]
  16. ParkI. PhanT.M. FangJ. Novel molecular mechanism of lenalidomide in myeloid malignancies independent of deletion of chromosome 5q.Cancers20211320508410.3390/cancers1320508434680233
     [Google Scholar]
  17. ListA. KurtinS. RoeD.J. BureshA. MahadevanD. FuchsD. RimszaL. HeatonR. KnightR. ZeldisJ.B. Efficacy of lenalidomide in myelodysplastic syndromes.N. Engl. J. Med.2005352654955710.1056/NEJMoa04166815703420
     [Google Scholar]
  18. GiagounidisA. MuftiG.J. FenauxP. GermingU. ListA. MacBethK.J. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: Linking mechanism of action to clinical outcomes.Ann. Hematol.201493111110.1007/s00277‑013‑1863‑524018623
     [Google Scholar]
  19. NiscolaP. TendasA. ScaramucciL. MerolaR. CatalanoG. de FabritiisP. Long-term hematological response in a patient with 5q- syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy.Blood Res.201449213013710.5045/br.2014.49.2.13025025016
     [Google Scholar]
  20. ListA.F. BennettJ.M. SekeresM.A. SkikneB. FuT. ShammoJ.M. NimerS.D. KnightR.D. GiagounidisA. MDS-003 Study Investigators Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.Leukemia20142851033104010.1038/leu.2013.30524150217
     [Google Scholar]
  21. OlivaE.N. LausekerM. Aloe SpiritiM.A. PoloniA. CortelezziA. PalumboG.A. BalleariE. SanpaoloG. VolpeA. RiccoA. RoncoF. AlatiC. D’ErrigoM.G. SantacaterinaI. KündgenA. GermingU. LatagliataR. Early lenalidomide treatment for low and intermediate-1 international prognostic scoring system risk myelodysplastic syndromes with del(5q) before transfusion dependence.Cancer Med.20154121789179710.1002/cam4.52326376955
     [Google Scholar]
  22. KomrokjiR.S. ListA.F. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.Ann. Oncol.2016271626810.1093/annonc/mdv48826504152
     [Google Scholar]
  23. GermingU. OlivaE.N. HiwaseD. AlmeidaA. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: Current and emerging strategies.HemaSphere201936e31410.1097/HS9.000000000000031431976486
     [Google Scholar]
  24. GurnariC. PiciocchiA. SodduS. BonanniF. ScalzulliE. NiscolaP. Di VeroliA. PiccioniA.L. PiedimonteM. MaioranaG. SalutariP. CicconiL. SantopietroM. GumenyukS. SarloC. FenuS. TafuriA. LatagliataR. FianchiL. CriscuoloM. MaciejewskiJ.P. MaurilloL. BuccisanoF. BrecciaM. VosoM.T. Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.Blood Cancer J.202212913210.1038/s41408‑022‑00724‑336071048
     [Google Scholar]
  25. LawalR.A. BanjokoO. NdulueC. AdebeshinS.T. SharifA. IghodaroO.E. OlusojiR. OdusanyaB. El-HamdiN. Improved side effect profile of alternate-day dosing of lenalidomide.Cureus2024163e5531710.7759/cureus.5531738559519
     [Google Scholar]
  26. PoloniA. Raaschou-JensenK. MohedoF.H. PaoliniS. OlivaE.N. BuccisanoF. VasconcelosA. KimI. MakwanaA. BernasconiD. RosettaniB. PrebetT. SantiniV. Lenalidomide in transfusion-dependent IPSS low- or intermediate-1-risk myelodysplastic syndromes and isolated del(5q): Results of a european postauthorization safety surveillance study.Clin. Lymphoma Myeloma Leuk.202410S2152S265010.1016/j.clml.2024.10.00739516085
     [Google Scholar]
  27. CrisàE. MoraE. GermingU. BallyC. Diez CampeloM. MyllymäkiM. JäderstenM. KomrokjiR. PlatzbeckerU. HaaseD. HofmannW.K. Al AliN.H. BarracoD. BargayJ.J. BernalT. López CadenasF. CalvisiA. CapodannoI. CerranoM. CianciaR. CrugnolaM. KündgenA. FinelliC. FozzaC. FrairiaC. FrejaE. GansterC. KubaschA.S. JimenezM.J. LatagliataR. Hernandez MohedoF. MoleroA. Vara PampliegaM. PerezC.A. PietrantuonoG. PoloniA. PomaresH. RecasensV. RüferA. SignoriA. Hellstrom-LindbergE. FenauxP. SanzG. SantiniV. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: A HARMONY Alliance study.Leukemia202438102259226510.1038/s41375‑024‑02360‑139103678
     [Google Scholar]
  28. GorsheinE. WeberU.M. GoreS. Higher-risk myelodysplastic syndromes with del(5q): Does the del(5q) matter?Expert Rev. Hematol.202013323323910.1080/17474086.2020.173080632067540
     [Google Scholar]
  29. DeZernA.E. GreenbergP.L. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.Blood2023142262258226710.1182/blood.202302008137562001
     [Google Scholar]
  30. Greenberg P.L. Tuechler H. Schanz J. SanzG. Garcia-ManeroG. SoléF. BennettJ.M. BowenD. FenauxP. DreyfusF. KantarjianH. KuendgenA. LevisA. MalcovatiL. CazzolaM. CermakJ. FonatschC. Le BeauM.M. SlovakM.L. KriegerO. LuebbertM. MaciejewskiJ. MagalhaesS.M.M. MiyazakiY. PfeilstöckerM. SekeresM. SperrW.R. StauderR. TauroS. ValentP. VallespiT. van de LoosdrechtA.A. GermingU. HaaseD. Revised international prognostic scoring system for myelodysplastic syndromes.Blood2012120122454246510.1182/blood‑2012‑03‑42048922740453
     [Google Scholar]
  31. VosoM.T. NiscolaP. PiciocchiA. FianchiL. MaurilloL. MustoP. PaganoL. MansuetoG. CriscuoloM. Aloe-SpiritiM.A. BuccisanoF. VendittiA. TendasA. PiccioniA.L. ZiniG. LatagliataR. FilardiN. FragassoA. FenuS. BrecciaM. GROM (Gruppo Romano e Laziale MDS) and Basilicata MDS Registry Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia.Eur. J. Haematol.201696434435110.1111/ejh.1259526018238
     [Google Scholar]
  32. ZeidanA.M. GoreS.D. KomrokjiR.S. Higher-risk myelodysplastic syndromes with del(5q): Is sequential azacitidine–lenalidomide combination the way to go?Expert Rev. Hematol.20136325125410.1586/ehm.13.3023782079
     [Google Scholar]
  33. PlatzbeckerU. BraulkeF. KündgenA. GötzeK. BugG. SchönefeldtC. ShirneshanK. RölligC. BornhäuserM. NaumannR. NeesenJ. GiagounidisA. HofmannW-K. EhningerG. GermingU. HaaseD. WermkeM. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: A phase I study.Leukemia20132761403140710.1038/leu.2013.2623354011
     [Google Scholar]
  34. KunacheewaC. ThongthangP. UngprasertP. UtchariyaprasitE. OwattanapanichW. A systematic review and meta - analysis of the efficacy and adverse events of azacitidine - plus - lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia.Hematology201924149850610.1080/16078454.2019.163142531221030
     [Google Scholar]
  35. RasmussenB. GöhringG. BernardE. NilssonL. TobiassonM. JäderstenM. GareliusH. DybedalI. GrønbaekK. EjerbladE. LorenzF. FlogegårdM. MarcherC.W. Öster FernströmA. CavelierL. PapaemmanuilE. EbelingF. KittangA.O. NørgaardJ.M. SaftL. MöllgårdL. Hellström-LindbergE. “Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”.Leukemia20223651436143910.1038/s41375‑022‑01537‑w35277655
     [Google Scholar]
  36. NiscolaP. MazzoneC. GiovanniniC. The value of tailored therapy on survival in high risk MDS with Del5q: Report of an unusual case.Ann. Case Rep.202381163
     [Google Scholar]
  37. OlivaE.N. LatagliataR. SabattiniE. MammìC. CuzzolaM. D’ErrigoM.G. CannatàM.C. BovaI. CapodannoI. PalumboG.A. PaneF. RedaG. FianchiL. RivaM. PoloniA. Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.Am. J. Blood Res.202111441742634540351
     [Google Scholar]
  38. OlivaE.N. PlatzbeckerU. FenauxP. Garcia-ManeroG. LeBlancT.W. PatelB.J. KubaschA.S. SekeresM.A. Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned.Blood Rev.20215010085110.1016/j.blre.2021.10085134088518
     [Google Scholar]
  39. SantiniV. AlmeidaA. GiagounidisA. PlatzbeckerU. BucksteinR. BeachC.L. GuoS. AltincatalA. WuC. FenauxP. The effect of lenalidomide on health-related quality of life in patients with lower-risk non-del(5q) myelodysplastic syndromes: Results from the MDS-005 study.Clin. Lymphoma Myeloma Leuk.2018182136144.e710.1016/j.clml.2017.12.00429429612
     [Google Scholar]
  40. NiscolaP. GianfeliciV. GiovanniniM. PiccioniD. MazzoneC. de FabritiisP. Quality of life considerations in myelodysplastic syndrome: Not only fatigue.Expert Rev. Hematol.202417840741010.1080/17474086.2024.237803538970288
     [Google Scholar]
  41. Palacios-BerraqueroM.L. Alfonso-PiérolaA. Current therapy of the patients with MDS: Walking towards personalized therapy.J. Clin. Med.20211010210710.3390/jcm1010210734068316
     [Google Scholar]
  42. EfficaceF. BucksteinR. AbelG.A. GiesingerJ.M. FenauxP. BewersdorfJ.P. BrunnerA.M. BejarR. BorateU. DeZernA.E. GreenbergP. RobozG.J. SavonaM.R. SparanoF. BoultwoodJ. KomrokjiR. SallmanD.A. XieZ. SanzG. CarrawayH.E. TaylorJ. NimerS.D. Della PortaM.G. SantiniV. StahlM. PlatzbeckerU. SekeresM.A. ZeidanA.M. Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS).HemaSphere202485e6910.1002/hem3.6938774655
     [Google Scholar]
  43. ChenY. ZhengJ. WengY. WuZ. LuoX. QiuY. LinY. HuJ. WuY. Myelodysplasia-related gene mutations are associated with favorable prognosis in patients with TP53-mutant acute myeloid leukemia.Ann. Hematol.202410341211122010.1007/s00277‑024‑05679‑y38409598
     [Google Scholar]
  44. KimD.Y. ShinD.Y. OhS. KimI. KimE.J. Gene expression and DNA methylation profiling suggest potential biomarkers for azacitidine resistance in myelodysplastic syndrome.Int. J. Mol. Sci.2024259472310.3390/ijms2509472338731939
     [Google Scholar]
  45. Noguera-Castells A. Campillo-MarcosI. DavalosV. García-PrietoC.A. ValcárcelD. MoleroA. PalomoL. GattermannN. WulfertM. Chaparro-GonzálezL. SoléF. CabezónM. Jiménez-LorenzoM.J. XicoyB. ZamoraL. De StefanoA. CasalinI. FinelliC. FolloM.Y. EstellerM. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.Br. J. Haematol.202420451838184310.1111/bjh.1939238471524
     [Google Scholar]
  46. SerranoG. BerasteguiN. Díaz-MazkiaranA. García-OlloquiP. Rodriguez-ResC. Huerga-DominguezS. AinciburuM. Vilas-ZornozaA. Martin-UrizP.S. Aguirre-RuizP. Ullate-AgoteA. AricetaB. Lamo-EspinosaJ.M. AchaP. CalveteO. JimenezT. MoleroA. MontoroM.J. Díez-CampeloM. ValcarcelD. SoléF. Alfonso-PierolaA. OchoaI. PrósperF. EzpondaT. HernaezM. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide.Nat. Commun.2024151527210.1038/s41467‑024‑49529‑x38902243
     [Google Scholar]
  47. GangatN. BellamN. ReichardK. TefferiA. Emergence of TP53 mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine.Haematologica202410941306130938031760
     [Google Scholar]
  48. AbdallahM. ReichardK. GangatN. TefferiA. Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – Lenalidomide related or disease-intrinsic clonal evolution?Blood Cancer J.20241414910.1038/s41408‑024‑01027‑538499527
     [Google Scholar]
  49. van de LoosdrechtA.A. CremersE.M.P. AlhanC. DuetzC. in ’t HoutF.E.M. Visser-WisselaarH.A. ChituD.A. VerbruggeA. CunhaS.M. OssenkoppeleG.J. JanssenJ.J.W.M. KleinS.K. VellengaE. HulsG.A. MuusP. LangemeijerS.M.C. de GreefG.E. te BoekhorstP.A.W. RaaijmakersM.H.G. van Marwijk KooyM. LegdeurM.C. WegmanJ.J. DeenikW. de WeerdtO. van Maanen-LammeT.M. JobseP. van KampenR.J.W. BeekerA. WijermansP.W. BiemondB.J. TanisB.C. van EsserJ.W.J. SchaarC.G. Noordzij-NooteboomH.S. JacobsE.M.G. de GraafA.O. Jongen-LavrencicM. Stevens-KroefM.J.P.L. WestersT.M. JansenJ.H. Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: The HOVON89 trial.Leukemia202438484085010.1038/s41375‑024‑02161‑638297135
     [Google Scholar]
  50. LachowiezC.A. RavikumarV.I. OthmanJ. O’NionsJ. PetersD.T. McMahonC. SwordsR. CookR. SaultzJ.N. TynerJ.W. DillonR.J. ZeidnerJ.F. PollyeaD.A. Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Blood2024blood.202402692510.1182/blood.202402692539486083
     [Google Scholar]
/content/journals/chamc/10.2174/0118715257341062250130103015
Loading

  • Article Type:     Case Report
Keyword(s): acute myeloid leukemia; azacytidine; Del5q alteration; High-risk myelodysplastic syndromes; lenalidomide; quality of life

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test